AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

Delisting risk

NSPR · NASDAQ · Medical - Devices

InspireMD (NSPR)

Develops CGuard mesh-covered carotid stents for stroke prevention.

$0.9132

Pre-market+0.04 (+5.04%)

At close$0.8694(−4.30%)

Watchlist

Something off on this page? Send us feedback.

Breakdown13F · 13D/G · Form 4

Institutions34 holders · as of Mar 31, 2026	49.05%	22.80M shares
Insiders13 holders · as of May 29, 2026	26.96%	12.53M shares
Strategic holders2 holders · as of Feb 2, 2026	6.83%	3.17M shares
Otherremainder	17.16%	7.98M shares

46.49M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing

Top shareholders13F · 13D/G · Form 4

Holder	Stake	Shares	Evidence
Rosalind Advisors, Inc.Institution	8.40%	3.91M	13Fas of Mar 31, 2026
Michael A. Lawless¹Insiderofficer: Chief Financial Officer	8.26%	3.61M	13Dfiled Jan 16, 2026 ↗
Nantahala Capital Management, LLCInstitution	7.26%	3.38M	13Fas of Mar 31, 2026
Abrdn PLCInstitution	6.83%	3.17M	13Fas of Mar 31, 2026
Aberdeen Group plcStrategic	6.83%	3.17M	13Gfiled Feb 2, 2026 ↗
Orbimed Advisors LLCInstitution	6.74%	3.13M	13Fas of Mar 31, 2026
Marvin Slosman²Insiderdirector, officer: CEO and President	5.54%	2.56M	13Dfiled May 13, 2026 ↗
Nantahala Capital Partners Limited PartnershipInstitution	5.20%	2.42M	13Gfiled Nov 14, 2025 ↗
Parkman Healthcare Partners LLCInstitution	5.20%	2.42M	13Fas of Mar 31, 2026
Velan Capital Investment Management LPInstitution	4.52%	2.10M	13Fas of Mar 31, 2026
Marshall Wace, LLPInstitution	4.00%	1.86M	13Fas of Mar 31, 2026
Craig Shore³Insiderofficer: CFO and CAO	2.39%	1.11M	Form 4filed Jan 10, 2025 ↗
Paul StukaInsiderdirector	2.39%	1.11M	Form 4filed May 29, 2026 ↗
Soleus Capital Management, L.P.Institution	2.25%	1.05M	13Fas of Mar 31, 2026
Andrea TommasoliInsiderofficer: Chief Operating Officer	2.05%	954,389	Form 4filed Jan 16, 2026 ↗
Gary S. RoubinInsiderdirector	1.79%	834,478	Form 4filed May 8, 2026 ↗
Michael BermanInsiderdirector	1.29%	597,580	Form 4filed Jan 16, 2026 ↗
Thomas J. KesterInsiderdirector	0.99%	458,573	Form 4filed Sep 17, 2025 ↗
Pura Vida Investments, LLCInstitution	0.97%	450,517	13Fas of Mar 31, 2026
Ingalls & Snyder LLCInstitution	0.82%	379,300	13Fas of Mar 31, 2026
Patrick VertaInsiderofficer: EVP Clinical/Medical Affairs	0.67%	311,532	Form 4filed Jan 10, 2025 ↗
Kathryn ArnoldInsiderdirector	0.65%	303,087	Form 4filed Dec 31, 2025 ↗
Affiance Financial, LLCInstitution	0.54%	250,370	13Fas of Mar 31, 2026
Scott R. WardInsiderdirector	0.51%	237,096	Form 4filed May 8, 2026 ↗
Essex Investment Management Co LLCInstitution	0.25%	114,085	13Fas of Mar 31, 2026

Michael A. Lawless's transaction reports restate only vehicles that traded; the 2025 ownership statement (3.61M) plus the 226.7K net shares acquired since is used instead.
Marvin Slosman's own ownership statement (13D, Apr 24, 2026) plus the 21.0K net shares acquired since reports fewer shares than the transaction reports; the statement is used.
Reported at 3.50% on Oct 29, 2025, under the 5% line, so no further filing is required.

13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report

Institutions13F, as of Mar 31, 2026

34 holders · 22.80M shares · 3 new positions · 7 increased · 10 reduced · 13 closed

Holder	Shares	% outstanding	Chg q/q	Filed
Rosalind Advisors, Inc.	3.91M	8.40%	0	May 14, 2026
Nantahala Capital Management, LLC	3.38M	7.26%	0	May 15, 2026
Abrdn PLC	3.17M	6.83%	0	Apr 29, 2026
Orbimed Advisors LLC	3.13M	6.74%	0	May 15, 2026
Parkman Healthcare Partners LLC	2.42M	5.20%	0	May 15, 2026
Velan Capital Investment Management LP	2.10M	4.52%	−44.0K	May 15, 2026
Marshall Wace, LLP	1.86M	4.00%	0	May 15, 2026
Soleus Capital Management, L.P.	1.05M	2.25%	−104.3K	May 14, 2026

Ownership statements13D/G · 5% or more, as filed

Holder	% of class	Shares	Form	Filed
Nantahala Capital Management, LLC	9.99%	4.82M	13G	May 15, 2026 ↗
Marshall Wace, LLP	9.99%	28.10M	13G	Nov 14, 2025 ↗
Rosalind Advisors, Inc.	9.20%	10.99M	13G	Feb 11, 2026 ↗
Michael A. Lawless	8.60%	3.61M	13D	Oct 29, 2025 ↗
Aberdeen Group plc	7.49%	3.17M	13G	Feb 2, 2026 ↗
Orbimed Advisors LLC	7.40%	3.13M	13G	Feb 17, 2026 ↗
Parkman Healthcare Partners LLC	5.80%	2.44M	13G	Nov 14, 2025 ↗
Nantahala Capital Partners Limited Partnership	5.68%	2.42M	13G	Nov 14, 2025 ↗
Marvin Slosman	5.18%	2.56M	13D	Apr 24, 2026 ↗

Insider tradesForm 4

Latest trades

Date	Insider	Type	Shares	Avg price	Owned after
May 27, 2026	Paul Stukadirector	Purchase	20,000	$0.8750	667,871
May 19, 2026	Shane Thomas Gleasonofficer: Chief Commercial Officer	Sale	22,778	$1.01	1,053,882
Feb 2, 2026	Shane Thomas Gleasonofficer: Chief Commercial Officer	Sale · 2 lots	4,941	$1.60	1,076,660
May 30, 2025	Shane Thomas Gleasonofficer: Chief Commercial Officer	Sale	7,186	$2.51	1,079,601
May 29, 2025	Shane Thomas Gleasonofficer: Chief Commercial Officer	Sale	3,760	$2.51	1,086,787
May 27, 2025	Shane Thomas Gleasonofficer: Chief Commercial Officer	Sale	1,572	$2.51	1,090,547
May 23, 2025	Shane Thomas Gleasonofficer: Chief Commercial Officer	Sale	2,482	$2.51	1,092,119
Feb 25, 2025	Shane Thomas Gleasonofficer: Chief Commercial Officer	Sale	10,000	$3.65	1,094,601
Feb 4, 2025	Shane Thomas Gleasonofficer: Chief Commercial Officer	Sale	5,132	$2.46	1,104,601
Feb 3, 2025	Shane Thomas Gleasonofficer: Chief Commercial Officer	Sale	7,073	$2.51	1,109,733

CongressHouse and Senate disclosures

Not reported.